Evaluation of Sofosbuvir plus Ribavirinin Treatment of Cirrhotic Hepatitis C Patients: An Egyptian Study | ||||
| Egyptian Journal of Medical Microbiology | ||||
| Article 3, Volume 28, Issue 1, January 2019, Page 15-22 | ||||
| Document Type: New and original researches in the field of Microbiology. | ||||
| DOI: 10.21608/ejmm.2019.282306 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Alaa Aboud1; Mostafa S. ABDEL-MOTaleb  2; Ehab M. Fahmy3
| ||||
| 1Department of Tropical Medicine, Faculty of Medicine, Beni-suef University, Egypt | ||||
| 2Department of Medical Microbiology and Immunology, Faculty of Medicine, Beni-Suef University, Egypt | ||||
| 3Department of Medical Microbiology and Immunology, Faculty of Medicine, Aswan University, Egypt | ||||
| Abstract | ||||
| Background: HCV infection is considered a major health issue in Egypt. Dual therapy of sofosbuvir and ribavirin is now available for treatment of HCV but has not widely used in the treatment of cirrhotic patients. Objectives: This study aims to evaluate the efficacy and safety of combined therapy of sofosbuvir with ribavirin as a treatment for chronic hepatitis C (CHC) patients genotype 4 with cirrhosis. Methodology: sixty chronic HCV patients with liver cirrhosis were evaluated (clinically, laboratory, sonoraphically, upper GI endoscopy and liver biopsy) before treatment then they were treated with sofosbuvir and Ribavirin for 6 months and followed-up by laboratory investigations every month during, at the end of treatment and 3 months after cessation of treatment to determine its efficacy and side effects. Results: SVR rate was 80%, non-responders rate was 1.7% and relapses rate was 18.3%. Conclusion: Dual therapy including sofosbuvir and ribavirin is an effective well tolerated choice for treating CHC patients (genotype 4) with liver cirrhosis. | ||||
| Keywords | ||||
| Chronic hepatitis C; Sofosbuvir; Ribavirin | ||||
|
Statistics Article View: 36 |
||||
